Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Written By Guest User

ππŒπ‘π€-πŸ–πŸ”πŸ, a novel muscarinic M4 positive allosteric modulator (PAM) discovered at the Warren Center for Neuroscience Drug Discovery (WCNDD), has entered Phase 1 clinical trials in collaboration with Neumora Therapeutics.

Read the Press release here β†’

Guest User
Previous

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Next

Craig Lindsley featured on Quantum Potential Podcast: Rewiring the Brain and Rethinking Pain